Eomesodermin is required for antitumor immunity mediated by 4-1BB-agonist immunotherapy

Chang Song1, Kavitha Sadashivaiah1, Aki Furusawa1, Eduardo Davila2, Koji Tamada3, and Arnob Banerjee1,*

1Program in Oncology; Greenebaum Cancer Center; Center for Stem Cell Research and Regenerative Medicine; Department of Medicine; University of Maryland School of Medicine; Baltimore, MD USA; 2Department of Otolaryngology; University of Maryland School of Medicine; Baltimore, MD USA; 3Department of Immunology and Cellular Signal Analysis; Yamaguchi University School of Medicine; Ube, Japan

Keywords: T cells, tumor immunotherapy, 4-1BB, eomesodermin, PD-1, Lag3

Abbreviations: 4-1BB/TNFRSF9, tumor necrosis factor receptor superfamily member 9; α4-1BB, agonistic anti-4-1BB antibody; Eomes, eomesodermin; Lag3, lymphocyte-activation gene 3; LCMV, lymphocytic choriomeningitis virus; PD-1, programmed cell death-1; Tbet, T-bet/Tbx21, T-box 21; TNFRS, tumor necrosis family receptor superfamily

CD8⁺ T cells in progressing tumors frequently fail to mount an effective antitumor response often in association with the expression of inhibitory receptors, including programmed cell death-1 (PD-1) and lymphocyte-activation gene 3 (Lag3). Using a lymphoma tumor model, we demonstrate that tumor-infiltrating CD8⁺ T cells from growing tumors co-express inhibitory receptors and co-stimulatory receptors, including 4-1BB (TNFRSF9) as well as high levels of 2 transcription factors, Eomesodermin (Eomes) and T-bet (Tbx21), critical determinants of CD8⁺ T cell fate. Immunotherapy with an agonistic anti-4–1-BB antibody altered the ratio of Eomes to T-bet expression in tumor-infiltrating CD8⁺ T cells by increasing Eomes and decreasing T-bet expression. 4-1BB-agonist immunotherapy was also associated with downregulated expression of the inhibitory receptors PD-1 and Lag3 on tumor-infiltrating CD8⁺ T cells, a molecular phenotype associated with subsequent attenuation of tumor growth. Furthermore, 4-1BB-agonist immunotherapy failed to effect tumor progression in mice with Eomes deficient T cells. However, upon resumption of tumor growth, tumor-infiltrating CD8⁺ T cells from treated animals continued to express high levels of Eomes as well as elevated levels of the inhibitory receptors PD-1 and Lag3. Our data suggest that tumor-infiltrating CD8⁺ T cells are poised between activation and inhibition as dictated by expression of both co-stimulatory receptors and inhibitory receptors and demonstrate that T cell expression of Eomes is necessary, but not sufficient, for efficacious 4-1BB-agonist-mediated immunotherapy.

4-1BB signaling in T cells is initiated by the recruitment of TNF receptor-associated factors 1 and 2, (TRAF1 and TRAF2, respectively) with the subsequent activation of the downstream signaling cascade, including the oncogenic NF-κB (Rel) transcription factors, and mitogen-activated protein kinase (MAPK) family members ERK, JNK, and p38 MAPK. While NF-κB activity leads to increased expression of the anti-apoptotic BCL2-related proteins Bfl-1 (Bcl2A1) and Bcl-XL (Bcl2L1), ERK promotes degradation of the pro-apoptotic regulatory protein Bim, thereby culminating in increased T-cell survival. More recently, a connection between 4-1BB signaling and the T-cell master transcription factor eomesodermin (Eomes) has been inferred from observations of high expression levels of Eomes in KLKG1² CD4⁺ and CD8⁺ tumor-infiltrating T cells after 4-1BB agonist antibody therapy in a mouse melanoma model. Eomes and T-bet (Tbx21), both members of the T-box family of transcription factors, have been implicated as critical determinants of effector cell activity and memory cell specification among CD8⁺ T cells responding to various acute infectious

*Correspondence to: Arnob Banerjee; Email: abanerjee@som.umaryland.edu
Submitted: 09/05/2013; Revised: 12/29/2013; Accepted: 12/29/2013; Published Online: 02/27/2014
Citation: Song C, Sadashivaiah K, Furusawa A, Davila E, Tamada K, Banerjee A. Eomesodermin is required for antitumor immunity mediated by 4-1BB-agonist immunotherapy. OncoImmunology 2014; 3:e27680; http://dx.doi.org/10.4161/onci.27680

www.landesbioscience.com Oncoimmunology e27680-1
Eomes and T-bet also appear to play a role in modulating T cell differentiation occurring during immunological responses to chronic viral infection. In support, two disparate subsets of CD8+ T cells marked by distinct expression patterns of T-bet and Eomes were found to be necessary for efficacious containment of chronic viral infection. These findings led us to wonder whether tumor-infiltrating CD8+ T cells occurring during tumor progression and 4-1BB-mediated tumor regression could be similarly divided into functionally unique subsets on the basis of differential Eomes and T-bet expression.

To address how the expression of Eomes and T-bet expression contributes to the immunologic activities of tumor-infiltrating CD8+ T cells, either untreated developing tumors and those responding to anti-4-1BB agonist antibody (α4-1BB) therapy, we interrogated a mouse model of thymic lymphoblastic malignancy in the setting of deficiency in Eomes, T-bet, or both. We found that α4-1BB-antibody therapy increased expression of Eomes and decreased expression of T-bet in tumor-infiltrating CD8+ T cells. We further observed that α4-1BB immunotherapy was associated with a decrease in T cell expression of the inhibitory receptors programmed cell death-1 (PD-1) and lymphocyte-activation gene 3 (Lag3) and, α4-1BB antibody-mediated antitumor immunity was ineffective in mice harboring T cells lacking Eomes. Our findings substantiate those of the recently published mouse melanoma study providing solid evidence for the α4-1BB immunotherapy-mediated elicitation of Eomes expressing T cells with distinct antitumor immunologic properties. We further extend these findings by elucidating a correlation between the down-regulation of the inhibitory receptors PD-1 and Lag3 on tumor-infiltrating CD8+ T cells and beneficial therapeutic response to α4-1BB antibody treatment.

Results

Tumor infiltrating CD8+ CD44hi T cells co-express Eomes and T-bet concurrently with select inhibitory and co-stimulatory receptors

CD8+ tumor-infiltrating lymphocytes (TILs) and CD8+ T cells responding to chronic viral infection are both subject to persistent antigen exposure. In the case of chronic viral infection, functionally distinct CD8+ T cell subsets distinguishable by variable expression levels of T-bet and Eomes have been previously identified. To determine whether CD8+ tumor-infiltrating lymphocytes (TILs) could be divided into distinct sub-populations based on Eomes and T-bet expression, we measured the expression of both transcription factors by intracellular staining and cytofluorimetric analysis of tumor-infiltrating CD8+ T cells from EG7 lymphoma-bearing mice. We observed a single population of CD8+ CD44hi TILs present in harvested EG7 tumors 21 d after tumor cell s.c. inoculation into the flank of C57BL/6 host mice. Tumors were enzymatically dissociated to a single cell suspension and cells were stained with fluorophore-conjugated antibodies against the indicated markers. Flow cytometry was performed by gating on CD8+ cells. (A) Dot plot showing the expression of T-bet and Eomes in CD8+ CD44hi cells among TILs vs. splenic controls. (B) Histograms of the expression of the indicated proteins in either CD8+ CD44lo or CD8+ CD44hi tumor or spleen control cells, as indicated. Data in (A) and (B) are representative of at least 3 independent experiments. (C) 5 × 10^4 OVA-specific CD8+ T cells magnetically enriched from spleen preparations from CD45.1 OT-I donor mice were adoptively transferred to each mouse by i.v. injection on the same day as EG7 flank tumor inoculation. TILs were harvested 21 d later and analyzed by flow cytometry, as above. Dot plots show expression of the indicated marker in CD45.1+ (donor derived) and CD45.1- (host derived) subsets of CD8+ CD44hi cells. Data are representative of three independent experiments. 4-1BB/TNFRSF9, tumor necrosis factor receptor superfamily member 9; Eomes, eomesodermin; CTLA4, cytotoxic T-lymphocyte antigen 4; Lag3, lymphocyte-activation gene 3; PD-1, programmed cell death-1; T-bet/Tbx21, T-box 21.

Figure 1. Co-expression of Eomes, T-bet, PD-1, Lag3, 4-1BB, andOX40 by CD8+ CD44hi infiltrating lymphocytes in EG7 tumors. (A–C) Cytofluorimetric analysis of tumor-infiltrating lymphocytes (TILs) present in harvested EG7 tumors 21 d after tumor cell s.c. inoculation into the flank of C57BL/6 host mice. Tumors were enzymatically dissociated to a single cell suspension and cells were stained with fluorophore-conjugated antibodies against the indicated markers. Flow cytometry was performed by gating on CD8+ cells. (A) Dot plot showing the expression of T-bet and Eomes in CD8+ CD44hi cells among TILs vs. splenic controls. (B) Histograms of the expression of the indicated proteins in either CD8+ CD44lo or CD8+ CD44hi tumor or spleen control cells, as indicated. Data in (A) and (B) are representative of at least 3 independent experiments. (C) 5 × 10^4 OVA-specific CD8+ T cells magnetically enriched from spleen preparations from CD45.1 OT-I donor mice were adoptively transferred to each mouse by i.v. injection on the same day as EG7 flank tumor inoculation. TILs were harvested 21 d later and analyzed by flow cytometry, as above. Dot plots show expression of the indicated marker in CD45.1+ (donor derived) and CD45.1- (host derived) subsets of CD8+ CD44hi cells. Data are representative of three independent experiments. 4-1BB/TNFRSF9, tumor necrosis factor receptor superfamily member 9; Eomes, eomesodermin; CTLA4, cytotoxic T-lymphocyte antigen 4; Lag3, lymphocyte-activation gene 3; PD-1, programmed cell death-1; T-bet/Tbx21, T-box 21.
observed expression of an additional inhibitory receptor Lag3 on a proportion of CD8+CD44hi TILs, although cytotoxic T-lymphocyte antigen 4 (CTLA-4), another negative regulator of T-cell responses, was not expressed. In contrast to the phenotypically distinct CD44high subset of CD8+ TILs, naïve (CD44low) CD8+ TILs resembled naïve CD8+ T cells from the spleen (Fig. 1B).

Although we found that CD8+ CD44hi TILs in our system do express T cell inhibitory receptors, co-stimulation through members of the TNF receptor superfamily, specifically 4-1BB, OX40 (Tnfrsf4), and CD40, could nevertheless, cause immunologic tumor regression as previously shown in mouse tumor models similar to EG7.18-20 In order to determine this immunotherapeutic potential in EG7 lymphomas, we examined the expression of these 3 TNF receptor superfamily members and found that 4-1BB and OX40 were expressed on CD8+ CD44hi TILs from EG7 tumors, whereas CD40 was not (Fig. 1B).

The distinct phenotype of CD8+ CD44hi TILs from EG7 tumors compared with those from splenocytes suggests that the TIL population is not composed solely of non-specific memory CD8+ T cells residing in the tumor. We next sought to determine whether the observed robust T-bet and Eomes expressivity and surface marker expression profile (PD-1+Lag3+4-1BB+OX40+) of the CD8+ CD44hi TILs matched that of tumor antigen-specific TILs. To measure the relative expression levels of these molecules in tumor-antigen specific TILs vs. CD8+ CD44hi TILs, we adoptively transferred T cells from OT-1 donor mice transgenic for a T cell receptor recognizing chicken ovalbumin-derived peptide (OVA) expressed by EG7 cells.21 Five × 10⁴ CD8+ T cells from OT-1 mice, distinguishable by expression of the congenic marker CD45.1 as opposed to expression of CD45.2 by endogenous T cells, were intravenously injected into tumor recipient mice coincidently with flank tumor inoculation. Analysis of TILs derived from resulting EG7 tumors revealed similar patterns of expression of the T-bet and Eomes transcription factors as well as all inhibitory and co-stimulatory receptors evaluated between OT-1 tumor-antigen specific TILs and endogenous CD8+ CD44hi TILs (Fig. 1C).

The data show that CD8+ CD44hi TILs in EG7 tumors are phenotypically distinct from memory CD8+ T cells while naïve CD8+ T cells in EG7 tumors resemble naïve CD8+ T cells in the spleen. CD8+ CD44hi TILs are marked by high expression of Eomes and T-bet and selective co-expression of inhibitory receptors and co-stimulatory receptors, a profile corresponding to that of tumor antigen-specific TILs. Taken together, our results suggest that although CD8+ CD44hi TILs express inhibitory receptors associated with T-cell exhaustion, they retain potential for activation through 4-1BB or OX40 ligation.

**Figure 2.** Diminished Lag3 expression on Eomes-deficient CD8+ CD44hi TILs. (A–C) 1 × 10⁶ EG7 cells were subcutaneously injected into the flank of 6–12 wk old C57Bl/6 wild-type (WT), Eomes KO (EKO), T-bet KO (TKO) or double KO (DKO) recipient mice. Data are representative of at least 3 independent experiments. (A) Cytofluorometric analysis of immunofluorescence stained, dissociated tumor cells 21 d after tumor cell inoculation. Histograms of the expression level of the indicated marker in CD8+ CD44hi splenocytes or EG7 tumor-infiltrating lymphocytes (TILs). (B) Growth curves for EG7 tumors in C57BL/6 controls vs. EKO, TKO, and DKO mice. Each point represents the mean ± SEM of tumor measurements (n = 8 per group). Statistical analyses were performed by Student’s t test with no significant differences between WT and EKO, TKO, or DKO at any time point (P > 0.05). (C) Quantitation of CD8+ CD44hi TILs in EG7 tumors from mice in (B), 21 d post tumor inoculation as determined by flow cytometry. Bars represent the mean ± SEM of the log CD8+ CD44hi TILs per gram tumor (n = 8 per group). Statistical analyses were performed by Student’s t test with no significant differences found between WT and EKO, TKO, or DKO (P > 0.05). 4-1BB/TNFRSF9, tumor necrosis factor receptor superfamily member 9; Eomes, eomesodermin; KO, knockout; Lag3, lymphocyte-activation gene 3; PD-1, programmed cell death-1; Tbet, T-bet/Tbx21, T-box 21;
Eomes and T-bet in CD8⁺ CD44hi TILs, we next sought to determine whether the expression of these cell surface molecules was Eomes or T-bet dependent. We analyzed CD8⁺ CD44hi TILs from EG7 tumors in CD4-Cre Eomes<sup>lox/lox</sup> (Eomes KO), Tbx21<sup>−/−</sup> (T-bet KO), or CD4-Cre Eomes<sup>lox/lox</sup> Tbx21<sup>−/−</sup> (double KO) mice. As shown in Figure 2A, whereas the expression of PD-1, 4-1BB, and OX40 by CD8⁺ CD44hi TILs was not significantly altered by the lack of Eomes, T-bet, or both, Lag3 levels were decreased specifically in CD8⁺ CD44hi TILs lacking Eomes.

In light of the scarce effect of Eomes and T-bet expression on the levels of CD8⁺ CD44hi TIL surface molecules, we next sought to determine the impact of Eomes and T-bet on EG7 tumor development and the frequency of TILs. As shown in Figure 2B–C, the observed tumor growth rates as well as the number of CD8⁺ CD44hi TILs were similar irrespective of the presence of Eomes, T-bet, or both. These findings suggest that although Eomes and T-bet are both expressed at high levels in CD8⁺ CD44hi TILs, the initial anti-EG7 tumor response is not substantially altered in the absence of either or both transcription factors, despite diminished expression of Lag3 in the absence of Eomes.

4-1BB ligation leads to increased Eomes and diminished T-bet expression in CD8⁺ CD44hi TILs

Variable tumor regression has been observed following administration of an agonistic anti-4-1BB directed antibody (α4-1BB), such that treatment is efficacious only in certain tumor models. Beneficial responses have been observed to occur in tumor models resembling EG7, whereas in other systems α4-1BB treatment has been shown to be ineffective or efficacious only when given in combination with another form of immunotherapy. To determine the efficacy of α4-1BB in our model of thymic lymphoblastic malignancy, we injected EG7 tumor-bearing mice with α4-1BB or control rat IgG2A and measured tumor growth over time. We observed no significant difference between the 2 groups in the first week after injection, however, subsequent stabilization of tumor size was observed in the α4-1BB group the following week (Fig. 3A). Tumors in the α4-1BB group typically remained stable in size for approximately one additional week prior to growth resumption. To determine whether the observed temporary arrest in tumor progression was associated with a change in T-box transcription factor levels, we analyzed CD8⁺ CD44hi TILs for expression of Eomes and T-bet 6 d after injection of α4-1BB. As shown in Figure 3B, Eomes expression in CD8⁺ CD44hi TILs, already elevated relative to the levels observed in memory CD8⁺ T cells, was further increased after α4-1BB administration. In contrast, T-bet expression was slightly diminished by the α4-1BB therapeutic regimen.

In CD4⁺ T cells, combined OX40 and 4-1BB co-stimulation has been previously shown to induce both Eomes and T-bet expression. More recently, another study demonstrated upregulation of Eomes in a KLRG1-expressing subset of B16 melanoma tumor-infiltrating T cells in response to immunotherapy with a tumor vaccine and a 4-1BB agonist antibody. KLRG1 is a cadherin receptor that has previously been shown to be associated with terminal differentiation and senescence in T cells and may also act as a T cell inhibitory receptor. To determine if there was a correlation between KLRG1 and Eomes in TILs responding to α4-1BB in our tumor model, we measured KLRG1 expression relative to Eomes and T-bet in CD8⁺ CD44hi TILs after α4-1BB administration in EG7 tumor-bearing mice (Fig. 3C). We observed high levels of KLRG1 expression in approximately half of the CD8⁺ CD44hi TILs and enriched among CD8⁺ CD44hi TILs in which Eomes was more abundant. The CD8⁺ CD44hi TILs that had diminished expression of T-bet, however, were almost uniformly KLRG1⁺. Taken together, these results demonstrate that Eomes and T-bet expression in CD8⁺
CD44hi TILs is altered by α4-1BB immunotherapy in EG7 tumor bearing mice. Considering the marked upregulation of Eomes expression observed in response to α4-1BB immunotherapy, we hypothesized that Eomes expression plays an important role in the delay in tumor progression elicited by this treatment regimen.

**Eomes is required for α4-1BB-mediated EG7 tumor growth retardation**

In order to determine whether Eomes expression in CD8+CD44hi TILs is essential for the attenuation of EG7 tumor growth in response to 4-1BB stimulation, we treated tumor-bearing mice from Eomes proficient or Eomes KO backgrounds with α4-1BB therapeutic antibody and monitored changes in tumor size over time. Whereas in Eomes proficient mice in which we observed tumor growth arrest with the same kinetics as in our prior experiments, Eomes KO mouse tumors continued to grow at the same rate as those in rat IgG2a control treated tumor-bearing hosts from either background (Fig. 4A).

We next investigated whether Eomes is required for a different form of antitumor immunotherapy. We tested whether immunization against the ovalbumin epitope expressed by EG7 tumor cells could alter tumor growth in Eomes KO mice. In sharp contrast to our findings with α4-1BB agonist antibody, immunization against ovalbumin co-administered with CpG oligodeoxynucleotide adjuvant slowed EG7 tumor growth in both Eomes proficient and Eomes deficient mice (Fig. 4B).

---

**Figure 4.** Eomes is required for α4-1BB mediated delay in tumor progression. (A) C57BL/6 (WT) or Eomes KO (EKO) mice bearing EG7 tumors were administered 100 μg α4-1BB or control rat IgG on d7 and d10 after tumor cell inoculation. Tumor growth curves are shown, with each point representing the mean ± SEM of the tumor area (n = 8 per group). Data are from one of three independent experiments. Statistical analyses were performed by Student t test; IgG vs. α4-1BB in WT mice *P < 0.05 and **P < 0.01 whereas in EKO mice no significant differences were detected between treatment groups. (B) Tumor growth curves for s.c. flank EG7 tumors in WT or EKO mice immunized by s.c. injection of phosphate-buffered saline (PBS) or CpG oligodeoxynucleotide and ovalbumin (CpG-OVA) 14d prior to tumor inoculation and on the day of tumor cell inoculation. Each point represents the mean ± SEM of the tumor area (n = 4 per group). Data are from one of two independent experiments. Statistical analyses were performed by Student t test for differences between PBS and CpG-OVA groups in WT mice (*P < 0.05 and **P < 0.01) or EKO mice (1P < 0.05 and 11P < 0.01). (C) Cytfluorometric analysis of immunofluorescence stained, dissociated tumor cells for KLRG1, PD-1 and Lag3 in CD8+CD44hi gated TILs from EG7 tumors 13d after tumor inoculation and 3d after the second dose of α4-1BB antibody (red line) or rat IgG (blue line) treatment in vivo. Isotype control staining of CD8+CD44hi gated TILs from IgG-treated animal is shown for comparison (black dashed line). Data are representative of 3 independent experiments. (D) Quantitation of lung nodules from WT or EKO mice 14 d after i.v. injection of B16 cells followed by administration of 100 μg α4-1BB or control rat IgG on d6 and d9 after B16 injection. Bars represent mean ± SEM of lung nodule counts (n = 5 per group). Data are from 1 of 2 independent experiments. Statistical analyses were performed by Student t test; IgG vs. α4-1BB groups *P < 0.05 in WT mice whereas no significant differences were detected between treatment groups in EKO mice. (E) Photo of representative lungs from each of the four groups from (D).
Eomes deficient CD8+ CD44hi TILs harvested 3 d after the second dose of α4-1BB antibody, a time frame coincident with tumor growth retardation, showed no increase in KLRG1 expression in response to α4-1BB (Fig. 4C). Our earlier experiments showed that CD8+ CD44hi TILs from untreated EG7 tumors co-express at least 2 inhibitory receptors, PD-1 and Lag3, along with 4-1BB. Following α4-1BB immunotherapy, we observed diminished expression of both PD-1 and Lag3 in CD8+ CD44hi TILs from WT animals (Fig. 4C). However, PD-1 expression remained stable in CD8+ CD44hi TILs from tumor-bearing Eomes KO mice given α4-1BB treatment relative to those derived from the IgG control-treated hosts. The expression of Lag3, which was not elevated in Eomes KO CD8+ CD44hi TILs even in large, growing tumors, was similarly not altered after α4-1BB antibody injection.

To establish whether Eomes is necessary for α4-1BB-mediated immunotherapy in a less immunogenic tumor model of non-lymphoid origin, we used B16 melanoma cells in an experimental lung metastasis model.17 Fourteen days after i.v. inoculation with B16 cells, α4-1BB antibody therapy resulted in a diminished number of B16 nodules occurring in the lungs of C57BL/6 mice whereas there was no effect on metastatic burden in Eomes KO mice (Fig. 4D–E). Taken together, our findings demonstrate that 4-1BB-agonist therapy can impair tumor growth through an Eomes-dependent mechanism and suggest that 4-1BB-agonist therapy has the potential to reverse inhibitory receptor expression in tumor-infiltrating CD8+ T cells.

CD8+ CD44hi TILs express high levels of Eomes, PD-1, and Lag3 during tumor progression following α4-1BB immunotherapy

We next analyzed TILs from EG7 tumors that had resumed growth after α4-1BB immunotherapy to determine whether the observed increase in Eomes expression and corresponding decrease in inhibitory receptor expression were lost. In fact, the elevated Eomes expression in CD8+ CD44hi TILs occurring after α4-1BB antibody administration persisted in TILs derived from tumors that had resumed growth post immunotherapy (Fig. 5). Furthermore, the Eomes expression profile in CD8+ CD44hi TILs derived from α4-1BB antibody vs. control rat IgG2a treated animals appeared similar upon tumor progression (12 d after therapy and 22 d post tumor-inoculation) to that of CD8+ CD44hi TILs derived from growth inhibited tumors (3 d after therapy and 13 d post tumor-inoculation).

In contrast to the increase in Eomes expression, the increased expression of KLRG1 and reduced expression of the inhibitory receptors, PD-1 and Lag3 was not maintained in CD8+ CD44hi TILs analyzed from progressing EG7 tumors in α4-1BB injected mice (Fig. 5). Twenty-two days after tumor inoculation, KLRG1 expression remained higher in CD8+ CD44hi TILs from α4-1BB treated mice than in those from control rat IgG2a injected mice, but seemed diminished relative to 9 d prior. Although initially distinct, by 22 d after tumor inoculation (12 d after the second dose of α4-1BB antibody), the expression of PD-1 and Lag3 in CD8+ CD44hi TILs after α4-1BB administration were similar to those observed in TILs derived from control rat IgG2a treated animals (Fig. 5). These data demonstrate that the effects of α4-1BB immunotherapy on CD8+ CD44hi TIL expression of Eomes, KLRG1, and inhibitory receptors are not absolutely linked, and suggest that upregulation of Eomes in CD8+ CD44hi TILs is not sufficient to maintain effective antitumor immunity.

Discussion

We report here a co-expression of 4-1BB stimulatory and inhibitory receptors on the surface of CD8+ CD44hi TILs. We further demonstrate that α4-1BB agonist immunotherapy leads to an increase in Eomes expression and, that an Eomes-dependent delay in tumor progression correlates with a transient decrease in the expression of the inhibitory receptors PD-1 and Lag3. This study corroborates and extends recently published findings in a B16 melanoma tumor model system showing Eomes-dependent differentiation of highly active, tumor infiltrating KLRG1hi T cells after 4-1BB directed therapy.12 In this study, authors showed that α4-1BB-agonist antibody effects multiple cell types in vivo, including CD4+ T cells, macrophages and dendritic cells, such that it remains possible that some of the effects we observed in CD8+ T cells after α4-1BB administration are indirect manifestations of α4-1BB antibody via other immune cells. Since the use of α4-1BB agonist antibody as an anticancer immunotherapy was first proposed, it has been assayed in a number of different tumor model systems with variable results.3,28-30 Some of these models require co-administration of additional therapy along with α4-1BB antibody.12,31-34 In this study, in response to α4-1BB agonist treatment alone was observed in mice bearing EG7 tumors similar to its use in early clinical trials.1,3,29,30
Attempts to identify the cellular targets of α4-1BB immunotherapy by selective cell depletion in vivo have consistently identified CD8+ T cells as essential to the therapeutic effect of α4-1BB. Depletion of NK cells has yielded inconsistent results, with loss of α4-1BB antibody mediated antitumor effects observed in some studies in contrast to no effect in others. CD4+ T cells appear to be unnecessary for α4-1BB mediated tumor immunity, with some evidence actually supporting the superior activity when α4-1BB antibody is combined with a depleting anti-CD4 antibody. In a different approach, Lin et al. examined the ability of α4-1BB to exert antitumor effects on the growth of EG7 tumors in contexts in which 4-1BB expression was restricted to specific immune cell populations.

Specifically, 4-1BB expression on αβ T cells was found to be necessary and sufficient for tumor inhibitory responses to α4-1BB. Expression of 4-1BB restricted to tumor-specific CD8+ T cells transferred into a 4-1BB deficient host was also found to be sufficient for α4-1BB mediated antitumor immunity. Therefore, these data suggest that our observations are due, at least in part, to the direct effects of α4-1BB agonist antibody on CD8+ T cells.

It remains unclear whether there is a threshold of T-bet and/or Eomes expression in CD8+ TILs that is either necessary or sufficient for long-lasting antitumor immunity. Prior work has shown relatively stable antitumor immune responses by tumor-vaccine stimulated CD8+ T cells lacking either T-bet or Eomes, although a deficiency in tumor infiltration has been demonstrated when T cells lack both transcription factors. In addition to the evinced induction of Eomes and KLRG1 co-expressing TILs in response to α4-1BB antibody, there is further evidence linking Eomes expression to T-cell anticancer activity. Induction of Eomes in CD4 T cells by co-stimulation with agonist antibodies directed against the co-stimulatory receptors, 4-1BB and OX-40 has been previously shown to be associated with antitumor activity in a melanoma model. The T cell inhibitory receptor, CTLA-4, has been shown to repress Eomes expression and antibody mediated blockade CTLA-4 has therapeutic activity in animal models and in cancer patients. While these data suggest that high Eomes expression in TILs is associated with tumor regression, Eomes alone is insufficient to ablate tumor development as our data show tumor progression despite continued expression of Eomes.

Our data do show a correlation between α4-1BB immunotherapy and transient decreased expression of the inhibitory receptors PD-1 and Lag3 on TILs. Insights into the complex interactions between T cell co-stimulatory pathways and inhibitory receptor signaling are highly relevant to the design of approaches to combinational immunotherapy. Pre-clinical studies in which α4-1BB agonist therapy has been combined with PD-1 or PD-L1 blockade in mouse models of hepatocellular carcinoma and chronic viral infection have demonstrated potential synergy between the two approaches. Our observation of diminished expression of PD-1 and Lag3 soon after α4-1BB therapy and increased expression upon tumor progression suggests that the timing and dosing of 4-1BB agonist and PD-1 antagonist approaches may have a significant impact on antitumor efficacy. This view is supported by the observation of sensitivity to relative dosing of α4-1BB vs. αPD-L1 antibodies eliciting optimal CD8+ T-cell response to chronic viral infection.

In addition to the temporary alteration of PD-1 and Lag3 expression after α4-1BB antibody administration, our data suggest a potential relationship between Eomes and Lag3 expression in CD8+ CD44hi TILs. Prior work has established a link between T-bet, which shares partial homology with Eomes, and the inhibitory receptor PD-1. In this case, T-bet has been shown to inhibit the expression of PD-1, whereas our data suggests that Eomes may positively regulate the expression of Lag3. However, the nature of the relationship between Eomes and Lag3 is confounded by the observation of increased Eomes expression and decreased Lag3 expression immediately after α4-1BB therapy. Nevertheless, the observation of high Eomes expression and high Lag3 expression on TILs upon tumor progression after α4-1BB therapy suggests that the earlier increase in Eomes expression and decrease in Lag3 expression may not be linked events.

In the setting of pathogen infection such as lymphocytic choriomeningitis virus (LCMV), control of chronic infection is dependent on the existence of 2 sub-populations of responding CD8+ T cells, a T-bet+ Eomes+ and a Tbet− Eomeshi population. Loss of either population leads to a loss of viral control and increased viral burden. In our EG7 tumors, we initially observed a single population of CD8+ T cells with regard to high levels of T-bet and Eomes expression. Immediately after α4-1BB therapy and coincident with controlled tumor growth, we observed an Eomeshi population that had relatively low expression of T-bet, and an Eomeslo population that had relatively higher expression of T-bet. Upon progression of EG7 tumor growth after α4-1BB therapy, we observed a single population of CD8+ T cells with elevated expression of Eomes and co-expression of the inhibitory receptors PD-1 and Lag3. In the LCMV model, T-bet ablation in T cells during chronic infection leads to high levels of Eomes and PD-1 expression in virus-reactive T cells, a molecular phenotype correlating with failure to contain the virus. The Eomeshi CD8+ T cell population in the setting of uncontrolled chronic LCMV infection was found to be phenotypically and functionally exhausted, and it is possible that T cell exhaustion accounts for the eventual failure of α4-1BB therapy in our system as well. Multiple strategies for combating T cell exhaustion in cancer are under development and α4-1BB directed therapy may be most effective in combination with an approach designed to prevent T cell exhaustion.

Re-expression of PD-1 and Lag3 in CD8+ CD44hi TILs with continued high levels of Eomes after α4-1BB immunotherapy demonstrates that Eomes expression is not sufficient to suppress the expression of inhibitory receptors. Although we did not observe downregulation of PD-1 in Eomes deficient TILs after α4-1BB therapy, the relationship between PD-1 expression and Eomes may be indirect in this setting. 4-1BB signaling has been shown to increase the survival of CD8+ T cells through the upregulation of the pro-survival Bcl-2 family members Bcl-2, Bfl-1 and Bcl-XL, and downregulation of the pro-apoptotic family member Bim. Our observations would be in keeping with a scenario in which Eomes is necessary for a
subset of α4-1BB mediated effects, such as α4-1BB stimulated TIL survival, but does not directly influence PD-1 downregulation. Overall our results are consistent with a model in which TILs can exist in a state poised between inhibition and reactivation with simultaneous expression of multiple inhibitory and co-stimulatory receptors. 4-1BB-agonist immunotherapy leads to increased expression of the master transcription factor Eomes and decreased expression of inhibitory receptors, tipping the balance toward TIL reactivation.

**Materials and Methods**

**Mice strains**

Mice were bred, housed and utilized in accordance with the University of Maryland School of Medicine Institutional Animal Care and Use Guidelines. C57BL/6 mice, OT-1 mice, and CD45.1 mice on a C57BL/6 background were initially obtained from The Jackson Laboratory. OT-1 mice and CD45.1 mice were crossed to obtain CD45.1 OT-1 mice. Tbx21−/− (T-bet KO) and CD4-Cre Eomesfl/fl (Eomes KO) mice on a C57BL/6 background were a generous gift of Dr. Steven Reiner (Columbia University).15 Tbx21−/− mice and CD4-Cre Eomesfl/fl mice were crossed to obtain Tbx21−/− CD4-Cre Eomesfl/fl (double KO) mice.

**Antibodies**

Fluorochrome-labeled antibodies to CD8, CD44, PD-1, Lag3, CTLA4, 4-1BB, CD40, OX40, KLRG1, CD45.1, T-bet, and Eomes were purchased from eBioscience. Anti-4-1BB antibody (rat IgG2A) utilized for in vivo applications has been previously described16 and was produced from hybridoma line 2A with permission from Dr. Lieping Chen (Yale University).

**Cell staining and flow cytometry**

Cells were stained with fluorochrome-labeled antibodies to cell surface molecules for 30 minutes at 4°C prior to fixation and permeabilization (FoxP3 / Transcription Factor Staining Buffer Set, eBioscience) and staining with fluorochrome-labeled antibodies to intracellular antigens. 1 × 10⁶ events per sample were acquired on an Accuri C6 (BD Biosciences) flow cytometer. Gating based on CD8 and CD44 surface staining (concomitant) and analysis was performed using FlowJo software (Treestar).

**Cell lines**

EG7 cells were purchased from ATCC and grown in RPMI 1640 (Life Technologies) supplemented with 10% fetal bovine serum (FBS), 2 mM L-glutamine, 100 U/mL penicillin G, 100 µg/mL streptomycin sulfate, 0.05 mM 2-mercaptoethanol, and 0.4 mg/mL G418. B16 melanoma cells were also purchased from ATCC and grown in Dulbecco’s modified Eagle’s medium (Life Technologies) supplemented with 10% FBS, 2 mM L-glutamine, 100 U/mL penicillin G, and 100 µg/mL streptomycin sulfate.

**Tumor transplantation models, immunotherapy and monitoring of tumor growth**

In the lymphoma model, 1 × 10⁶ EG7 cells in 200 µL phosphate-buffered saline (PBS) were subcutaneously injected into flank of 6–12 wk old C57BL/6, Eomes KO (EKO), T-bet KO (Tbx21−/−) mice or double KO recipient mice. Tumors were measured in both the vertical and horizontal dimensions using a caliper and the measurements were used to calculate tumor area at the indicated time points. In some experiments, EG7 tumor-bearing wild-type C57BL/6, Eomes KO (EKO), T-bet KO (Tbx21−/−) mice or double KO were treated with i.p. administration of 100 µg α4-1BB or control rat IgG on day 7 and day 10 after tumor inoculation. In the lung nodule model, 3 × 10⁵ B16 cells in 200 µL PBS were intravenously injected into 6–12 wk old C57BL/6 mice. After 14 d mice were euthanized and lungs were harvested and fixed in Fekete’s solution prior to counting of surface tumor nodules.

**Immunization**

Ovalbumin (OVA) and unmethylated CpG oligonucleotide (CPG) were both purchased from Invivogen. Injected solution contained 1 mg/mL OVA and 0.5 mg/mL CPG in PBS. 100 µL of this solution (vs. PBS control) was administered by s.c. injection 14 d prior to tumor inoculation and again on the day of tumor cell inoculation.

**Tumor harvesting and preparation of tumor-infiltrating T cells**

For analyses of TILs in the absence of immunotherapy (as in Figs. 1 and 2) tumors were harvested 21 d after inoculation. For analyses of TILs responding to antibody administration (as in Figs. 3 and 4) tumors were harvested 3 d after the final dose of agonistic anti-4-1BB antibody corresponding to 13 d after the initial tumor cell inoculation. For analysis of TILs responding to antibody administration vs. TILs from treatment-resistant tumors that resumed growth after antibody administration (as in Figs. 5) tumors were harvested 6 or 15 d after the first of 2 doses of antibody (13 or 22 d after initial tumor inoculation), as indicated. Tumors were measured prior to sacrifice and excised tumors were weighed. Tumors were minced, digested with Collagenase Type 2 (Life Technologies) and DNAase (Roche), and homogenized to a single cell suspension.

**Adapptive T cell transfer**

Spleens were collected from CD45.1 OT-1 donor mice and CD8+ T cells were isolated magnetically using a CD8+ T cell isolation kit (Miltenyi). CD8+ T cells were resuspended in PBS at a concentration of 2.5 × 10⁶ cells/ml. 200 µL of the cell suspension was transferred to each recipient by i.v. injection.

**Statistical Analysis**

Statistical analyses were performed as indicated using the 2-tailed Student t test. A P value of less than 0.05 was considered significant.

**Disclosure of Potential Conflicts of Interest**

No potential conflicts of interest were disclosed.

**Acknowledgments**

This work was supported by National Institute of Health grants (P30CA134274, K08HL93207), the Gabrielle’s Angel Foundation for Cancer Research, and the Marlene and Stewart Greenebaum Cancer Center. We thank Curt Civin for assistance and discussion.
References

1. Melero I, Hirschhorn-Cymerman D, Morales-Kastreana A, Sammaned MF, Wolchok JD. Antigen associated to infected T cells. The molecules that costimulate CD8+ and NK cells. Clin Cancer Res 2013; 19:10443-5; PMID:23466355; http://dx.doi.org/10.1186/1078-0343.CCR-12-2865

2. Moran AE, Kowacsics-Bankowski M, Weinberg AG, Thompson AB, 4-IBB, and CD40 as targets for cancer immunotherapy. Curr Opin Immunol 2013; 25:230-7; PMID:23414607; http://dx.doi.org/10.1016/j.coi.2013.01.004

3. Vinay DS, Kwon BS. Immunotherapy of cancer with 4-IBB. Mol Cancer Ther 2012; 11:1062-70; PMID:22695856; http://dx.doi.org/10.1158/1535-7163.MCT-11-0677

4. Peggs KS, Qazeda SA, Allison JP. Cancer immunotherapy: co-stimulatory agonists and co-inhibitory antagonists. Clin Exp Immunop 2009; 157:9-19; PMID:19697565; http://dx.doi.org/10.1111/j.1365-2362.2009.03912.x

5. Ascieto PA, Simeone E, Snil M, Fu YX, Melero I. Clinical experiences with anti-CD137 and anti-PDI therapeutic antibodies. Semin Oncol 2010; 37:508-16; PMID:20704670; http://dx.doi.org/10.1053/j.semincancer.2010.09.008

6. Lin GH, Liu Y, Abagala T, Kwon BS, Ohashi PS, Watts TH. Evaluating the cellular targets of anti-4-IBB agonist during immunotherapy of a pre-established tumor in mice. PLoS One 2010; 5:e11003; PMID:21148582; http://dx.doi.org/10.1371/journal.pone.0011003

7. May KF Jr., Chen L, Zheng P, Liu Y. Anti-4-1BB monoclonal antibody enhances rejection of large tumor burden by promoting survival but not clonal expansion of tumor-specific CD8+ T cells. Cancer Res 2002; 62:3459-65; PMID:12607989

8. Miller RE, Jones J, Le T, Whitmore J, Boiani N, et al. In vivo depletion of DC impairs the antitumor effect of agonistic anti-CD137 mAb. Eur J Immunol 2004; 34:2861-7; PMID:15128063; http://dx.doi.org/10.1002/eji.200341384

9. Wilcox RA, Flies DB, Zhu G, Johnson AJ, Tamada K, Chapoval AI, Strome SE, et al. CD134 plus CD137 dual costimulation induces Eomesodermin in a CD40-dependent manner. J Immunol 2002; 168:2720-8; PMID:12180765; http://dx.doi.org/10.1084/jem.20021190

10. Hoggins KA, Jameson SC, Heath WR, Howard JL, Bevan MJ, Carbone FR. T cell receptor antagonist peptides induce positive selection. Cell 1994; 76:17-27; PMID:8287479; http://dx.doi.org/10.1016/0092-8674(94)90169-4

11. Kim JA, Averbuch BJ, Chambers K, Rothchild K, Kjaergaard J, Papay R, Shu S. Divergent effects of 4-IBB antibodies on antitumor immunity and on tumor-reactive T-cell generation. Cancer Res 2001; 61:2031-7; PMID:11280763

12. Murillo O, Dubrov J, Palazón A, Arina A, Azpilikueta I, et al. In vivo depletion of DC impairs the antitumor effect of agonistic anti-CD137 mAb. Eur J Immunol 2009; 39:2424-36; PMID:19662633; http://dx.doi.org/10.1002/eji.200838958

13. Li Q, Iuchi T, Jure-Kunkel MN, Chang AE. Antigen dependent effect of anti-4-1BB mAb administration in adoptive T cell therapy of cancer. Int J Biochem Cell Biol 2007; 39:455-62; PMID:17081758; http://dx.doi.org/10.1016/j.biocel.2007.01.023

14. Snell LM, Lin GH, McPherson AJ, Moraes TJ, Watts TH. T-cell intrinsic effects of GITR and 4-IBB during viral infection and cancer immunotherapy. Immunol Rev 2011; 244:217-27; PMID:2207440; http://dx.doi.org/10.1111/j.1600-065X.2011.01063.x

15. Lynch DA. The promise of 4-IBB (CD137)-mediated immunomodulation and the immunotherapy of cancer. Immunol Rev 2008; 222:277-86; PMID:18364008; http://dx.doi.org/10.1111/j.1600-065X.2008.00621.x

16. Liu F, Li Q, Shen P, Korsmeyer SJ, Greten FR, Jure-Kunkel MN, Teitz-Ten bumper S, Chang AE. Anti-CD137 monoclonal antibody administration augments the antitumor efficacy of dendritic cell-based vaccines. Cancer Res 2004; 64:8411-9; PMID:15548712; http://dx.doi.org/10.1158/0008-5472.CAN-04-0590

17. Choi BK, Kim YH, Kang WJ, Lee SK, Kim KH, Shin SM, Yokoyama WM, Kim TY, Kwon BS. Mechanisms involved in synergistic anticancer immunity of anti-4-IBB and anti-CD4 therapy. Cancer Res 2007; 67:8891-9; PMID:17875731; http://dx.doi.org/10.1158/0008-5472.CAN-07-1056

18. Ko E, Luo W, Peng L, Wang X, Ferrone S. Mouse dendritic-endothelial cell hybrids and 4-IBB costimulation elicit antitumor effects mediated by broad anti-angiogenic immunity. Cancer Res 2007; 67:7875-84; PMID:17697994; http://dx.doi.org/10.1158/0008-5472.CAN-06-1744

19. Kim YH, Choi BK, Oh HS, Kang WJ, Mitrler RS, Kwon BS. Mechanisms involved in synergistic anti-cancer effects of anti-4-IBB and cyclophosphamide therapy. Mol Cancer Ther 2009; 8:469-78; PMID:19190115; http://dx.doi.org/10.1158/1535-7163.MCT-08-0993

20. Melero I, Johnston JV, Shufford WW, Mitrler RS, Chen L. NK.1.1 cells express 4-IBB (CD137) costimulatory molecule and are required for tumor immu- nity elicited by anti-4-IBB monoclonal antibodies. Cell Immunol 1998; 190:167-72; PMID:9878117; http://dx.doi.org/10.1006/cimm.1998.1396

21. Martiner O, Ermekeva V, Qiao JQ, Sauter B, Mandel H, Chen L, NLK1 cells express 4-IBB (CD137) costimulatory molecule and are required for tumor immu- nity elicited by anti-4-IBB monoclonal antibodies. Cell Immunol 1998; 190:167-72; PMID:9878117; http://dx.doi.org/10.1006/cimm.1998.1396

22. Jay ET, Guelinckx G, Plauchu H, Taitinen N, Aftila A, Khairat A, Kor del A, Chen L, et al. Therapeutic effect of CD137 immunomodulation in lymphoma and its enhance- ment by Treg depletion. Blood 2009; 114:3451-8; PMID:19490725; http://dx.doi.org/10.1182/blood-2009-05-223958

23. Murillo O, Dubrov J, Palazón A, Arina A, Arpirkika A, Alfarco C, Solano O, Ochoa MC, Berasain C, Gabarri I, et al. In vivo depletion of DC impacts the anti-tumor effect of agonistic anti-CD137 mAb. Eur J Immunol 2009; 39:2424-36; PMID:19662633; http://dx.doi.org/10.1002/eji.200838958

24. Li Q, Iuchi T, Jure-Kunkel MN, Chang AE. Antigen dependent effect of anti-4-1BB mAb administration in adoptive T cell therapy of cancer. Int J Biochem Cell Biol 2007; 39:455-62; PMID:17081758; http://dx.doi.org/10.1016/j.biocel.2007.01.023

25. Zha Y, Xu J, Chen E, Dai S, Li C, Morel P, Liu L, Zhang X, Lu B. T-bet and eomesodermin are required for T cell-mediated antitumor immune responses. J Immunol 2010; 184:6071-9; PMID:20713880; http://dx.doi.org/10.4049/jimmunol.100749

26. Hegel JK, Krueke K, Kolar P, Reiner SL, Brunner-Weinzierl MC. CD152 (CTLA-4) regulates effector functions of CD8+ T lymphocytes by repressing eomesodermin. Eur J Immunol 2009; 39:883-93; PMID:19224637; http://dx.doi.org/10.1002/eji.200838770
42. Wolchok JD, Hodi FS, Weber JS, Allison JP, Urba WJ, Robert C, O’Day SJ, Hoos A, Humphrey R, Berman DM, et al. Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma. Ann N Y Acad Sci 2013; 1291:1-13; PMID:23772560; http://dx.doi.org/10.1111/nyas.12180

43. Grosso JF, Jure-Kunkel MN. CTLA-4 blockade in tumor models: an overview of preclinical and translational research. Cancer Immun 2013; 13:5; PMID:23390376

44. Melero I, Grimaldi AM, Perez-Gracia JL, Ascierto PA. Clinical development of immunostimulatory monoclonal antibodies and opportunities for combination. Clin Cancer Res 2013; 19:997-1008; PMID:23460531; http://dx.doi.org/10.1158/1078-0432.CCR-12-2214

45. Vezys V, Penaloza-MacMaster P, Barber DL, Ha SJ, Konieczny B, Freeman GJ, Mirtler RS, Ahmed R. 4-1BB signaling synergizes with programmed death ligand 1 blockade to augment CD8 T cell responses during chronic viral infection. J Immunol 2011; 187:1634-42; PMID:21742975; http://dx.doi.org/10.4049/jimmunol.1100077

46. Xiao H, Huang B, Yuan Y, Li D, Han LF, Liu Y, Gong W, Wu FH, Zhang GM, Feng ZH. Soluble PD-1 facilitates 4-1BBL-triggered antitumor immunity against murine H22 hepatocarcinoma in vivo. Clin Cancer Res 2007; 13:1823-30; PMID:17325342; http://dx.doi.org/10.1158/1078-0432.CCR-06-2154

47. Kao C, Oestreich KJ, Paley MA, Crawford A, Angelosanto JM, Ali MA, Intlekofer AM, Boss JM, Reiner SL, Weinmann AS, et al. Transcription factor T-bet represses expression of the inhibitory receptor PD-1 and sustains virus-specific CD8+ T cell responses during chronic infection. Nat Immunol 2011; 12:663-71; PMID:21623380; http://dx.doi.org/10.1038/ni.2046

48. Goding SR, Wilson KA, Xie Y, Harris KM, Baxi A, Akpinarli A, Fulton A, Tamada K, Strom SE, Antonys PA. Restoring immune function of tumor-specific CD4+ T cells during recurrence of melanoma. J Immunol 2013; 190:4899-909; PMID:23536636; http://dx.doi.org/10.4049/jimmunol.1300271

49. Sakuishi K, Ngiow SF, Sullivan JM, Teng MW, Kuchroo VK, Smyth MJ, Anderson AC. TIM3(+)FOXP3(+) regulatory T cells are tissue-specific promoters of T-cell dysfunction in cancer. Oncoimmunology 2015; 2:e23849; PMID:23734331; http://dx.doi.org/10.4161/onci.23849

50. Goldberg MV, Drake CG. LAG-3 in Cancer Immunotherapy. Curr Top Microbiol Immunol 2011; 344:269-78; PMID:21086108; http://dx.doi.org/10.1007/82_2010_114

51. Speiser DE. A molecular profile of T-cell exhaustion in cancer. Oncoimmunology 2012; 1:369-71; PMID:22737618; http://dx.doi.org/10.4161/onci.18342

52. Hernandez-Chacon JA, Li Y, Wu RC, Bertanetch C, Wang Y, Weber JS, Hwu P, Radvanyi LG. Costimulation through the CD137/4-1BB pathway protects human melanoma tumor-infiltrating lymphocytes from activation-induced cell death and enhances antitumor effector function. J Immunother 2011; 34:236-50; PMID:21389874; http://dx.doi.org/10.1097/CJI.0b013e318209e7ec

53. Wang C, Wen T, Routy JP, Bernard NF, Sekaly RP, Watts TH. 4-1BBL induces TNF receptor-associated factor 1-dependent Bim modulation in human T cells and is a critical component in the costimulation-dependent rescue of functionally impaired HIV-specific CD8 T cells. J Immunol 2007; 179:8252-63; PMID:18056369